Reciprocal Regulation of γ-globin Expression by Exo-miRNAs: Relevance to γ-globin Silencing in β-thalassemia Major
Authors
Affiliations
Induction of fetal hemoglobin (HbF) is a promising strategy in the treatment of β-thalassemia major (β-TM). The present study shows that plasma exosomal miRNAs (exo-miRs) are involved in γ-globin regulation. Exosomes shuttle miRNAs and mediate cell-cell communication. MiRNAs are regulators of biological processes through post-transcriptional targeting. Compared to HD (Healthy Donor), β-TM patients showed increased levels of plasma exosomes and the majority of exosomes had cellular origin from CD34+ cells. Further, HD and β-TM exosomes showed differential miRNA expressions. Among them, deregulated miR-223-3p and miR-138-5p in β-TM exosomes and HD had specific targets for γ-globin regulator and repressor respectively. Functional studies in K562 cells showed that HD exosomes and miR-138-5p regulated γ-globin expression by targeting BCL11A. β-TM exosomes and miR-223-3p down regulated γ-globin expression through LMO2 targeting. Importantly, miR-223-3p targeting through sponge repression resulted in γ-globin activation. Further, hnRNPA1 bound to stem-loop structure of pre-miR-223 and we found that hnRNPA1 knockdown or mutagenesis at miR-223-3p stem-loop sequence resulted in less mature exo-miR-223-3p levels. Altogether, the study shows for the first time on the important clinical evidence that differentially expressed exo-miRNAs reciprocally control γ-globin expressions. Further, the hnRNPA1-exo-miR-223-LMO2 axis may be critical to γ-globin silencing in β-TM.
Efficacy and safety of thalidomide in patients with β-thalassemia intermedia and major.
Ju W, Din G, Huang J, Zheng M, Wang X, Liu L Medicine (Baltimore). 2024; 103(43):e40328.
PMID: 39470504 PMC: 11521010. DOI: 10.1097/MD.0000000000040328.
Lv A, Chen M, Zhang S, Zhao W, Li J, Lin S Mol Med Rep. 2024; 31(1).
PMID: 39450557 PMC: 11529187. DOI: 10.3892/mmr.2024.13372.
Li T, Qin C, Zhao B, Li Z, Wang Y, Zhao Y Transl Cancer Res. 2024; 13(9):4846-4865.
PMID: 39430819 PMC: 11483359. DOI: 10.21037/tcr-24-54.
Potential Use of MicroRNA Technology in Thalassemia Therapy.
Rujito L, Wardana T, Siswandari W, Nainggolan I, Sasongko T J Clin Med Res. 2024; 16(9):411-422.
PMID: 39346566 PMC: 11426174. DOI: 10.14740/jocmr5245.
Transcriptional Repressor BCL11A in Erythroid Cells.
Zheng G, Orkin S Adv Exp Med Biol. 2024; 1459:199-215.
PMID: 39017845 DOI: 10.1007/978-3-031-62731-6_9.